Astrazeneca Ab

Astra Aktiebolag

Aktiebolaget Hassle

Aktiebolaget Astra

Per Johan Lundberg

Helene Depui

Christer Karlsson

Adam Rosinski

Bengt Magnus Lindstedt

Malin S&ouml;derbom

Kjell Hjalmar Andersson

Kurt Ingmar Lovgren

Mikael Thune

Brita Sj&ouml;blom

Alfred Sickmuller

Anders Sandberg

Berit Nilsson

Per-Gunnar Karehill

Brigitte Bauer

Leif Simonsson

Karin Wingstrand

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID

An enteric coated pharmaceutical dosage form comprising an H ,K -ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H ,K - ATPase inhibitor to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pulsed delayed release and another fraction with instant release of the H ,K -ATPase inhibitor. The portions are released in time by from 0.5 and up to 12 hours interval, preferably by from 0.5 and up to 8 hours, and more preferably by from 0.5 and up to 4 hours interval. The dosage form is intended for once daily administration.

Oral pharmaceutical pulsed release dosage form

An enteric coated pharmaceutical extended release dosage form of a H , K -ATPase inhibitor giving an extended plasma concentration profile of a H , K -ATPase inhibitor. The extended plasma profile is obtained by a pharmaceutical composition which comprises a core material of a hydrophilic or hydrophobic matrix, and the H , K -ATPase inhibitor and optionally pharmaceutically acceptable excipients. The dosage form may be administered once daily.

Oral pharmaceutical extended release dosage form

A drug delivery system for oral administration in solid dry form of a greasy/oily/sticky substance and a pharmaceutically active substance or a pharmaceutically active substance which itself is greasy/oily/sticky characterized by having a plurality of porous inorganic particles of small size incorporated with considerable amounts of greasy/oily/sticky substances and having fast release characteristics and a process for the preparation of such porous inorganic particles containing greasy/oily/sticky substances.

Porous hydroxyapatite particles as carriers for drug substances

A drug delivery system for oral administration in solid dry form of greasy/oily/sticky substance(s) and pharmaceutically active substance(s) or pharmaceutically active substance(s) which itself/themselves is/are greasy/oily/sticky) characterized by having a plurality of solid, polymeric matrix beads comprising considerable amounts of greasy/oily/sticky substances and having fast release characteristics and a process for the preparation of such solid, polymeric matrix beads comprising greasy/oily/sticky substances.

Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances

The present invention is related to an effervescent pharmaceutical preparation comprising effervescent excipients and a plurality of individual units comprising a pharmaceutically active compound and optional excipients wherein the units (,) are provided with a floating generating system. The floating generating systems comprises at least two coating layers, one of which is a gas generating layer (,) and the other layer is a barrier layer (,) enclosing the generated gas. Furthermore the invention is related to a process for the manufacture of the dosage forms, and their use in medicine.

Multiple unit effervescent dosage form

Multiple unit effervescent dosage forms comprising proton pump inhibitor

Pharmaceutical composition containing the ace inhibitor ramipril and a

Method of making a pharmaceutical dosage form comprising a proton pump

A preparation of a pharmacologically active ionizable substance, wherein active substance is ionically complexed to an ion-exchanger resin, which is embedded in a hydrophilid eroding matrix as well as a process for the manufacture thereof.

Pharmaceutical formulations containing a pharmacologically active

A preparation of a pharmacologically active ionizable substance, wherein active substance is ionically complexed to an ion-exchanger resin, which is embedded in a hydrophilic eroding matrix as well as a process for the manufacture thereof.

A method for the manufacture of oral controlled release dosage units containing hydroxypropyl methylcellulose wherein the aqueous granulation is performed in the presence of one or more solutes, which inhibit gel formation during the granulation but allows the formation of a gel when administered orally. Also the new dosage units prepared according to the invention are included.

Growing community of inventors

Molndal, Sweden

Per Johan Lundberg